Kinase drug discovery 20 years after imatinib: progress

Nature Reviews Drug Discovery
20, 551-569
DOI: 10.1038/s41573-021-00195-4

Citation Report

#	Article	IF	Citations
1	TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs. Pharmaceuticals, 2021, 14, 632.	1.7	15
3	Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades. Pharmaceuticals, 2021, 14, 710.	1.7	27
4	Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors. Cancers, 2021, 13, 3531.	1.7	9
5	Editorial: Heading Against Parasitic Resistance: A Screen for Next Generation Drugs Against Targets of cAMP- or cGMP-regulated Pathways. Frontiers in Microbiology, 2021, 12, 727978.	1.5	1
6	Structure based design, synthesis, and evaluation of anti-CML activity of the quinolinequinones as LY83583 analogs. Chemico-Biological Interactions, 2021, 345, 109555.	1.7	18
7	Gene Duplication and Gene Fusion Are Important Drivers of Tumourigenesis during Cancer Evolution. Genes, 2021, 12, 1376.	1.0	13
8	Angiocrine Regulation of Epithelial Barrier Integrity in Inflammatory Bowel Disease. Frontiers in Medicine, 2021, 8, 643607.	1.2	13
9	Assessing the Inhibitory Potential of Kinase Inhibitors In Vitro: Major Pitfalls and Suggestions for Improving Comparability of Data Using CK1 Inhibitors as an Example. Molecules, 2021, 26, 4898.	1.7	5
10	Direct Target Site Identification of a Sulfonylâ€“Triazole Covalent Kinase Probe by LC-MS Chemical Proteomics. Analytical Chemistry, 2021, 93, 11946-11955.	3.2	10
11	Chemical Probes for Understudied Kinases: Challenges and Opportunities. Journal of Medicinal Chemistry, 2022, 65, 1132-1170.	2.9	15
12	Targeting the Integrated Stress Response Kinase GCN2 to Modulate Retroviral Integration. Molecules, 2021, 26, 5423.	1.7	3
13	Targeting CD82/KAI1 for Precision Therapeutics in Surmounting Metastatic Potential in Breast Cancer. Cancers, 2021, 13, 4486.	1.7	3
14	Chromosomal instability and aneuploidy as causes of cancer drug resistance. Trends in Cancer, 2022, 8, 43-53.	3.8	27
15	Design and Development of a Chemical Probe for Pseudokinase Ca2+/calmodulin-Dependent Ser/Thr Kinase. Journal of Medicinal Chemistry, 2021, 64, 14358-14376.	2.9	3
16	Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents. Frontiers in Molecular Biosciences, 2021, 8, 741316.	1.6	59
17	Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma. Lung Cancer, 2021, 161, 68-75.	0.9	8
18	Polyamine homeostasis-based strategies for cancer: The role of combination regimens. European Journal of Pharmacology, 2021, 910, 174456.	1.7	7
19	Characterizing the role of the dark kinome in neurodegenerative disease â€“ A mini review. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 130014.	1.1	3

#	Article	IF	Citations
20	Small Molecule Kinase Inhibitor Drugs (1995â€“2021): Medical Indication, Pharmacology, and Synthesis. Journal of Medicinal Chemistry, 2022, 65, 1047-1131.	2.9	114
21	Discovery of a Potent and Highly Isoform-Selective Inhibitor of the Neglected Ribosomal Protein S6 Kinase Beta 2 (S6K2). Cancers, 2021, 13, 5133.	1.7	5
22	Icotinib, Almonertinib, and Olmutinib: A 2D Similarity/Docking-Based Study to Predict the Potential Binding Modes and Interactions into EGFR. Molecules, 2021, 26, 6423.	1.7	3
23	Cardiometabolic consequences of targeted anticancer therapies. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	0.8	3
24	Protein kinase A Mediated Effects of Protein kinase C Partial Agonist HMI-1a3 in Colorectal Cancer Cells. Journal of Pharmacology and Experimental Therapeutics, 2021, , JPET-AR-2021-000848.	1.3	2
25	Degradation of Protein Kinases: Ternary Complex, Cooperativity, and Selectivity. ACS Medicinal Chemistry Letters, 2021, 12, 1629-1632.	1.3	4
26	Targeted Therapies in Cancer: To Be or Not to Be, Selective. Biomedicines, 2021, 9, 1591.	1.4	15
28	Synthesis and evaluation of hydrogen peroxide sensitive tofacitinib prodrugs. European Journal of Medicinal Chemistry Reports, 2022, 4, 100019.	0.6	1
30	Kinase Inhibitorsâ€™ Effects on Innate Immunity in Solid Cancers. Cancers, 2021, 13, 5695.	1.7	5
31	p38 Mediates Resistance to FGFR Inhibition in Non-Small Cell Lung Cancer. Cells, 2021, 10, 3363.	1.8	6
32	Recent Trends in Rationally Designed Molecules as Kinase Inhibitors. Current Medicinal Chemistry, 2023, 30, 1529-1567.	1.2	4
33	Interdisciplinary team science to understand and intercept rare cancers. Molecular and Cellular Oncology, 2021, 8, 1997331.	0.3	0
34	Nek2 Kinase Signaling in Malaria, Bone, Immune and Kidney Disorders to Metastatic Cancers and Drug Resistance: Progress on Nek2 Inhibitor Development. Molecules, 2022, 27, 347.	1.7	6
35	The active kinome: The modern view of how active protein kinase networks fit in biological research. Current Opinion in Pharmacology, 2022, 62, 117-129.	1.7	10
36	Identification and analysis of a selective DYRK1A inhibitor. Biomedicine and Pharmacotherapy, 2022, 146, 112580.	2.5	8
37	Supervised learning with word embeddings derived from PubMed captures latent knowledge about protein kinases and cancer. NAR Genomics and Bioinformatics, 2021, 3, lqab113.	1.5	4
39	Roadmap on plasticity and epigenetics in cancer. Physical Biology, 2022, 19, 031501.	0.8	8
40	Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicology and Applied Pharmacology, 2022, 434, 115823.	1.3	9

#	Article	IF	Citations
41	The Downregulation of Both Giant HERCs, HERC1 and HERC2, Is an Unambiguous Feature of Chronic Myeloid Leukemia, and HERC1 Levels Are Associated with Leukemic Cell Differentiation. Journal of Clinical Medicine, 2022, 11, 324.	1.0	4
42	An overview of in silico methods used in the design of VEGFR-2 inhibitors as anticancer agents. ChemistrySelect, 2023, 8, 2441-2457.	0.7	0
43	Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacological Research, 2022, 175, 106037.	3.1	136
44	Apoptosis in Type 2 Diabetes: Can It Be Prevented? Hippo Pathway Prospects. International Journal of Molecular Sciences, 2022, 23, 636.	1.8	9
45	Kinase Function of Brassinosteroid Receptor Specified by Two Allosterically Regulated Subdomains. Frontiers in Plant Science, 2021, 12, 802924.	1.7	4
46	Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?. Journal of Medicinal Chemistry, 2022, 65, 1735-1748.	2.9	16
47	Invited Commentary: Novel Cellular Immunotherapy (CAR T-Cell) in the Reading Room. Radiographics, 2022, 42, E21-E22.	1.4	0
48	Medicines for millions of patients. RSC Medicinal Chemistry, 2022, 13, 7-12.	1.7	1
49	Designing of kinase hinge binders: A medicinal chemistry perspective. Chemical Biology and Drug Design, 2022, 100, 968-980.	1.5	11
50	Machine learning for multi-omics data integration in cancer. IScience, 2022, 25, 103798.	1.9	78
51	The promise of TRK inhibitors in pediatric cancers with NTRK fusions. Cancer Genetics, 2022, 262-263, 71-79.	0.2	9
53	Why 90% of clinical drug development fails and how to improve it?. Acta Pharmaceutica Sinica B, 2022, 12, 3049-3062.	5.7	348
54	The Study of Microbeâ€“Host Two-Way Communication. Microorganisms, 2022, 10, 408.	1.6	2
55	The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. Clinical Science, 2022, 136, 197-222.	1.8	86
56	Glioblastoma, IDH-Wild Type With FGFR3-TACC3 Fusion: When Morphology May Reliably Predict the Molecular Profile of a Tumor. A Case Report and Literature Review. Frontiers in Neurology, 2022, 13, 823015.	1.1	11
57	Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 58-83.	2.9	46
58	Oxidative Stress in Cancer: Therapeutic Implications of Small-Molecule Kinase Inhibitors. , 2022, , 1-17.		0
59	C5â€iminosugar modification of casein kinase 1Î´ lead 3â€(4â€fluorophenyl)â€5â€isopropylâ€4â€(pyridinâ€4â€yl)isoxazole promotes enhanced inhibitor affinity and selectivity. Archiv Der Pharmazie, 2022, 355, e2100497.	2.1	2

#	Article	IF	Citations
60	A human kinase yeast array for the identification of kinases modulating phosphorylationâ€dependent proteinâ€“protein interactions. Molecular Systems Biology, 2022, 18, e10820.	3.2	9
61	Regulatory spine RS3 residue of protein kinases: a lipophilic bystander or a decisive element in the small-molecule kinase inhibitor binding?. Biochemical Society Transactions, 2022, 50, 633-648.	1.6	1
62	Synthesis of thieno[2,3-c]pyridine derived GRK2 inhibitors. Monatshefte FÃ¼r Chemie, 0, , 1.	0.9	1
63	OpenCADD-KLIFS: A Python package to fetch kinase data from the KLIFS database. Journal of Open Source Software, 2022, 7, 3951.	2.0	4
64	What are the current challenges for machine learning in drug discovery and repurposing?. Expert Opinion on Drug Discovery, 2022, 17, 423-425.	2.5	12
65	Drug-Targeted Genomes: Mutability of Ion Channels and GPCRs. Biomedicines, 2022, 10, 594.	1.4	6
66	Solid Tumors and Kinase Inhibition: Management and Therapy Efficacy Evolution. International Journal of Molecular Sciences, 2022, 23, 3830.	1.8	2
67	Principles of Kinase Allosteric Inhibition and Pocket Validation. Journal of Medicinal Chemistry, 2022, 65, 5288-5299.	2.9	19
68	Small molecule inhibitors of mammalian glycosylation. Matrix Biology Plus, 2022, 16, 100108.	1.9	6
70	Shining Light on Protein Kinase Biomarkers with Fluorescent Peptide Biosensors. Life, 2022, 12, 516.	1.1	1
72	Role of integrin Î±2 in methotrexate-induced epithelial-mesenchymal transition in alveolar epithelial A549 cells. Toxicological Research, 2022, 38, 449-458.	1.1	0
74	Platelet-derived growth factor signalling in neurovascular function and disease. International Journal of Biochemistry and Cell Biology, 2022, 145, 106187.	1.2	4
75	Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia. Pharmacological Research, 2022, 178, 106156.	3.1	30
76	Validation of an LCâ€“MS/MS Method for the Quantification of the CK2 Inhibitor Silmitasertib (CX-4945) in Human Plasma. Molecules, 2022, 27, 2394.	1.7	2
77	Multicomponent synthesis, cytotoxicity, and computational studies of novel imidazopyridazine-based N-phenylbenzamides. Journal of Saudi Chemical Society, 2022, 26, 101449.	2.4	4
78	Analysis of protein phosphorylation using Phos-tag gels. Journal of Proteomics, 2022, 259, 104558.	1.2	33
79	Enhancing autophagy in Alzheimer's disease through drug repositioning. , 2022, 237, 108171.		35
80	Active Site Sequence Representations of Human Kinases Outperform Full Sequence Representations for Affinity Prediction and Inhibitor Generation: 3D Effects in a 1D Model. Journal of Chemical Information and Modeling, 2022, 62, 240-257.	2.5	14

#	Article	IF	Citations
81	Comprehensive Profiling of Mammalian Tribbles Interactomes Implicates TRIB3 in Gene Repression. Cancers, 2021, 13, 6318.	1.7	7
84	Aurora A and AKT Kinase Signaling Associated with Primary Cilia. Cells, 2021, 10, 3602.	1.8	7
85	Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase. Frontiers in Cell and Developmental Biology, 2021, 9, 808864.	1.8	14
86	Introductory Chapter: Protein Kinases as Promising Targets for Drug Design against Cancer. Biochemistry, 0, , .	0.8	5
87	Detecting endogenous TRIB2 protein expression by flow cytometry and Western blotting. Methods in Enzymology, 2022, 667, 59-77.	0.4	0
89	Insulin action and resistance are dependent on a GSK3Î²-FBXW7-ERRÎ± transcriptional axis. Nature Communications, 2022, 13, 2105.	5.8	17
91	Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer. Nature Reviews Cardiology, 2022, 19, 414-425.	6.1	23
92	Exploring the kinase-inhibitor fragment interaction space facilitates the discovery of kinase inhibitor overcoming resistance by mutations. Briefings in Bioinformatics, 2022, 23, .	3.2	5
93	Encoding BRAF inhibitor functions in protein degraders. RSC Medicinal Chemistry, 2022, 13, 731-736.	1.7	4
94	Bioluminescent Zebrafish Transplantation Model for Drug Discovery. Frontiers in Pharmacology, 2022, 13, 893655.	1.6	5
95	Overcoming Cancer Drug Resistance Utilizing PROTAC Technology. Frontiers in Cell and Developmental Biology, 2022, 10, 872729.	1.8	32
96	Imatinib Mesylate Reduces Neurotrophic Factors and pERK and pAKT Expression in Urinary Bladder of Female Mice With Cyclophosphamide-Induced Cystitis. Frontiers in Systems Neuroscience, 2022, 16, 884260.	1.2	2
97	Recent Advances in Fluorescent Chemosensors for Protein Kinases. Chemistry - an Asian Journal, 2022, 17, .	1.7	1
98	A Toolbox of Fluorescent Peptide Biosensors to Highlight Protein Kinases in Complex Samples: Focus on Cyclinâ€Ðependent Kinases. European Journal of Organic Chemistry, 2022, 2022, .	1.2	2
99	Parkinsonâ€™s Disease and SARS-CoV-2 Infection: Particularities of Molecular and Cellular Mechanisms Regarding Pathogenesis and Treatment. Biomedicines, 2022, 10, 1000.	1.4	5
100	KiSSim: Predicting Off-Targets from Structural Similarities in the Kinome. Journal of Chemical Information and Modeling, 2022, 62, 2600-2616.	2.5	3
101	Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy. Oncogenesis, 2022, 11, 22.	2.1	16
102	Understanding the P-Loop Conformation in the Determination of Inhibitor Selectivity Toward the Hepatocellular Carcinoma-Associated Dark Kinase STK17B. Frontiers in Molecular Biosciences, 2022, 9, .	1.6	6

#	Article	IF	Citations
103	Therapeutic implication of carbon monoxide in drug resistant cancers. Biochemical Pharmacology, 2022, 201, 115061.	2.0	4
104	Intein-Mediated Protein Engineering for Cell-Based Biosensors. Biosensors, 2022, 12, 283.	2.3	1
105	Unlocking the Untapped Potential of Endothelial Kinase and Phosphatase Involvement in Sepsis for Drug Treatment Design. Frontiers in Immunology, 2022, 13, .	2.2	8
106	Naphthoquinone as a New Chemical Scaffold for Leishmanicidal Inhibitors of Leishmania GSK-3. Biomedicines, 2022, 10, 1136.	1.4	4
107	Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer. International Journal of Molecular Sciences, 2022, 23, 5476.	1.8	2
108	Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management. Minerva Medica, 2022, 113, 315-332.	0.3	3
109	Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules. Trends in Pharmacological Sciences, 2022, 43, 866-881.	4.0	13
110	Drug discovery for cancer therapy with special reference to inhibitors of protein kinase pathway. , 2022, , 71-96.		2
112	Investigating the Mechanism of Inhibition of Cyclin-Dependent Kinase 6 Inhibitory Potential by Selonsertib: Newer Insights Into Drug Repurposing. Frontiers in Oncology, 0, 12, .	1.3	3
114	Phenotypic drug discovery: recent successes, lessons learned and new directions. Nature Reviews Drug Discovery, 2022, 21, 899-914.	21.5	81
115	The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug. Journal of Medicinal Chemistry, 2022, 65, 7581-7594.	2.9	11
116	Expedient Access to Type II Kinase Inhibitor Chemotypes by Microwave-Assisted Suzuki Coupling. , 2022, 1, 64-72.		2
117	Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. OncoImmunology, 2022, 11, .	2.1	9
118	Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease. Cancer Letters, 2022, 547, 215775.	3.2	7
119	Targeting protein kinases benefits cancer immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188738.	3.3	5
120	Retro Drug Design: From Target Properties to Molecular Structures. Journal of Chemical Information and Modeling, 2022, 62, 2659-2669.	2.5	5
121	Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. Frontiers in Oncology, 0, 12, .	1.3	8
122	Catalytic activity in vitro of the human protein kinase ASK1 mutants: experimental and molecular simulation study. Computational Biology and Chemistry, 2022, , 107712.	1.1	2

#	Article	IF	Citations
123	Posttranslational Regulation of Inflammasomes, Its Potential as Biomarkers and in the Identification of Novel Drugs Targets. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	5
124	Deathâ€associated protein kinases and intestinal epithelial homeostasis. Anatomical Record, 2023, 306, 1062-1087.	0.8	4
126	Targeting drug-resistant mutations in ALK. Nature Cancer, 2022, 3, 659-661.	5.7	1
127	Targeting TMEM88 as an Attractive Therapeutic Strategy in Malignant Tumors. Frontiers in Oncology, 0, 12, .	1.3	3
128	Ageing â€“ Oxidative stress, PTMs and disease. Molecular Aspects of Medicine, 2022, 86, 101099.	2.7	37
129	JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	11
130	Explainable machine learning for medicinal chemistry: exploring multi-target compounds. Future Medicinal Chemistry, 2022, 14, 1171-1173.	1.1	2
131	Harnessing systematic proteinâ€“ligand interaction fingerprints for drug discovery. Drug Discovery Today, 2022, 27, 103319.	3.2	19
132	ERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	9
133	Immune-related adverse events of cancer immunotherapies targeting kinases. , 2022, , 108250.		1
134	The Conformational Transition Pathways and Hidden Intermediates in DFG-Flip Process of c-Met Kinase Revealed by Metadynamics Simulations. Journal of Chemical Information and Modeling, 0, , .	2.5	4
135	Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model. Biochemical and Biophysical Research Communications, 2022, 621, 157-161.	1.0	8
136	Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas. European Journal of Cancer, 2022, 173, 71-90.	1.3	9
137	Perturbation of biological processes with small molecule kinase inhibitors. Current Opinion in Chemical Biology, 2022, 70, 102185.	2.8	1
138	Discovery and evaluation of cytisine N-isoflavones as novel EGFR/HER2 dual inhibitors. Bioorganic Chemistry, 2022, 127, 105868.	2.0	10
139	Polymeric nanoparticles surface-complexed with boric acid actively target solid tumors overexpressing sialic acid. Journal of Colloid and Interface Science, 2022, 626, 916-929.	5.0	6
140	Recent advances in targeting protein kinases and pseudokinases in cancer biology. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	4
141	Insight into the mechanism of molecular recognition between human Integrin-Linked Kinase and Cpd22 and its implication at atomic level. Journal of Computer-Aided Molecular Design, 0, , .	1.3	3

#	Article	IF	Citations
142	Mechanistic Insights into the Mechanism of Inhibitor Selectivity toward the Dark Kinase STK17B against Its High Homology STK17A. Molecules, 2022, 27, 4655.	1.7	3
143	Novel Dicarboximide BK124.1 Breaks Multidrug Resistance and Shows Anticancer Efficacy in Chronic Myeloid Leukemia Preclinical Models and Patientsâ€™ CD34+/CD38â^' Leukemia Stem Cells. Cancers, 2022, 14, 3641.	1.7	1
144	Exploring the roles of the Cdc2-like kinases in cancers. Bioorganic and Medicinal Chemistry, 2022, 70, 116914.	1.4	3
145	Precision Medicine in Therapy of Non-solid Cancer. Handbook of Experimental Pharmacology, 2022, , .	0.9	0
146	KOPI: Kinase inhibitOr Proteome Impact analysis. Scientific Reports, 2022, 12, .	1.6	0
147	Repurposing of a human antibody-based microarray to explore conserved components of the signalome of the parasitic nematode Haemonchus contortus. Parasites and Vectors, 2022, 15, .	1.0	1
148	Decreased DNA Damage and Improved p53 Specificity of RITA Analogs. Molecular Cancer Therapeutics, 2022, 21, 1524-1534.	1.9	1
149	Multi or Single-Kinase Inhibitors to Counteract Drug Resistance in Cancer: What is New?. Current Medicinal Chemistry, 2023, 30, 776-782.	1.2	5
150	The cyclin G-associated kinase (GAK) inhibitor SGC-GAK-1 inhibits neurite outgrowth and synapse formation. Molecular Brain, 2022, 15, .	1.3	1
151	Comparative Assessment of Quantification Methods for Tumor Tissue Phosphoproteomics. Analytical Chemistry, 2022, 94, 10893-10906.	3.2	2
152	Novel Design Strategies to Enhance the Efficiency of Proteolysis Targeting Chimeras. ACS Pharmacology and Translational Science, 2022, 5, 710-723.	2.5	11
153	The Structureâ€“property Relationships of Clinically Approved Protein Kinase Inhibitors. Current Medicinal Chemistry, 2023, 30, 2518-2541.	1.2	1
154	Construction of Covalent Bisubstrate Inhibitor of Protein Kinase Reacting with Cysteine Residue at Substrate-Binding Site. Journal of Medicinal Chemistry, 2022, 65, 10975-10991.	2.9	3
155	Hotspot Identification and Drug Design of Proteinâ€“Protein Interaction Modulators Using the Fragment Molecular Orbital Method. Journal of Chemical Information and Modeling, 2022, 62, 3784-3799.	2.5	10
156	The synthesis of PROTAC molecule and new target KAT6A identification of CDK9 inhibitor iCDK9. Chinese Chemical Letters, 2023, 34, 107741.	4.8	5
157	Nanomedicines for Overcoming Cancer Drug Resistance. Pharmaceutics, 2022, 14, 1606.	2.0	9
158	The protein kinase CK1: Inhibition, activation, and possible allosteric modulation. Frontiers in Molecular Biosciences, 0, 9, .	1.6	3
159	Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy. Journal of Molecular Modeling, 2022, 28, .	0.8	5

#	Article	IF	Citations
160	Systematic Analysis and Prediction of the Target Space of Bioactive Food Compounds: Filling the Chemobiological Gaps. Journal of Chemical Information and Modeling, 2022, 62, 3734-3751.	2.5	5
161	A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy. Nature Communications, 2022, 13, .	5.8	6
162	Imatinib induces diastolic dysfunction and ventricular early-repolarization delay in the halothane-anesthetized dogs: Class effects of tyrosine kinase inhibitors. Journal of Pharmacological Sciences, 2022, , .	1.1	0
163	Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. Pharmacological Research, 2022, 183, 106362.	3.1	33
164	Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy. Cellular Signalling, 2022, 99, 110434.	1.7	10
165	Discovery of a selective c-MET inhibitor with a novel binding mode. Bioorganic and Medicinal Chemistry Letters, 2022, 75, 128948.	1.0	5
166	Switching from ultrafast electron transfer to proton transfer in excited drugâ€“protein complexes upon biotransformation. Chemical Science, 2022, 13, 9644-9654.	3.7	1
167	Protein Tyrosine Phosphatase Biochemical Inhibition Assays. Bio-protocol, 2022, 12, .	0.2	5
168	Oxidative Stress in Cancer: Therapeutic Implications of Small-Molecule Kinase Inhibitors. , 2022, , 3809-3825.		0
169	An attention mechanism-based LSTM network for cancer kinase activity prediction. SAR and QSAR in Environmental Research, 2022, 33, 631-647.	1.0	0
170	The MASTL-ENSA-PP2A/B55 axis modulates cisplatin resistance in oral squamous cell carcinoma. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	5
172	Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	51
173	Genomic mapping of copy number variations influencing immune response in breast cancer. Frontiers in Oncology, 0, 12, .	1.3	0
174	HOXB13 facilitates hepatocellular carcinoma progression by activating AKT/mTOR signaling pathway. Annals of Hepatology, 2022, , 100759.	0.6	0
175	Target-specific compound selectivity for multi-target drug discovery and repurposing. Frontiers in Pharmacology, 0, 13, .	1.6	7
176	Identification of Activating Mutations in the Transmembrane and Extracellular Domains of EGFR. Biochemistry, 2022, 61, 2049-2062.	1.2	1
177	Synthesis of N-(4-chlorophenyl) substituted pyrano[2,3-c]pyrazoles enabling PKBÎ²/AKT2 inhibitory and inÂvitro anti-glioma activity. Annals of Medicine, 2022, 54, 2548-2560.	1.5	16
178	Urea-based anticancer agents. Exploring 100-years of research with an eye to the future. Frontiers in Chemistry, 0, 10, .	1.8	11

#	Article	IF	Citations
179	Phosphorylation, compartmentalization, and cardiac function. IUBMB Life, 2023, 75, 353-369.	1.5	3
181	Current therapeutic options for glioblastoma and future perspectives. Expert Opinion on Pharmacotherapy, 2022, 23, 1629-1640.	0.9	5
182	Integrated and High-Throughput Approach for Sensitive Analysis of Tyrosine Phosphoproteome. Analytical Chemistry, 2022, 94, 13728-13736.	3.2	2
183	DSTYK inhibition increases the sensitivity of lung cancer cells to T cellâ€“mediated cytotoxicity. Journal of Experimental Medicine, 2022, 219, .	4.2	6
184	Crystal structure of the Rho-associated coiled-coil kinase 2 inhibitor belumosudil bound to CK2Î±. Acta Crystallographica Section F, Structural Biology Communications, 2022, 78, 348-353.	0.4	1
185	A convenient synthesis of (3S,3aR,5R,7aS,8S)-Hexahydro-4H-3,5-methanofuro[2,3-b]pyran-8-ol, a high-affinity nonpeptidyl ligand for highly potent HIV-1 protease inhibitors. Tetrahedron Letters, 2022, , 154161.	0.7	0
186	Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics. Pathobiology, 2023, 90, 166-175.	1.9	0
187	Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer. Cancer Treatment Reviews, 2022, 110, 102466.	3.4	4
188	Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue. , 2022, , .		0
189	Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer. Biomolecules, 2022, 12, 1590.	1.8	6
191	Systematic Exploration of Privileged Warheads for Covalent Kinase Drug Discovery. Pharmaceuticals, 2022, 15, 1322.	1.7	3
192	DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Research, 2023, 51, D1263-D1275.	6.5	28
193	Umpolung Synthesis of Pyridyl Ethers by Bi^Vâ€Mediated Oâ€Arylation of Pyridones. Angewandte Chemie - International Edition, 2022, 61, .	7.2	8
194	Peptideâ€Based Inhibitors that Target the Docking Site of ERK2. Israel Journal of Chemistry, 2022, 62, .	1.0	0
195	Thiadiazole Functionalized Salicylaldehyde-Schiff Base as a pH-responsive and chemo-reversible â€œTurn-Offâ€•fluorescent probe for selective cu (II) detection: Logic Gate Behaviour and Molecular Docking Studies. Journal of Fluorescence, 2023, 33, 25-41.	1.3	4
196	Large-Scale Crystallographic Fragment Screening Expedites Compound Optimization and Identifies Putative Proteinâ€“Protein Interaction Sites. Journal of Medicinal Chemistry, 2022, 65, 14630-14641.	2.9	5
197	Umpolung Synthesis of Pyridyl Ethers by Bi(V)â€Mediated Oâ€‘Arylation of Pyridones. Angewandte Chemie, 0, , .	1.6	0
198	Molecular targeted therapy for anticancer treatment. Experimental and Molecular Medicine, 2022, 54, 1670-1694.	3.2	57

#	Article	IF	Citations
199	Small molecule inhibitors targeting the cancers. MedComm, 2022, 3, .	3.1	25
200	PARP10 Mediates Mono-ADP-Ribosylation of Aurora-A Regulating G2/M Transition of the Cell Cycle. Cancers, 2022, 14, 5210.	1.7	4
201	Small-molecule inhibition of the archetypal UbiB protein COQ8. Nature Chemical Biology, 2023, 19, 230-238.	3.9	4
203	4-Thiazolidinone-Bearing Hybrid Molecules in Anticancer Drug Design. International Journal of Molecular Sciences, 2022, 23, 13135.	1.8	25
204	The Pursuit of Enzyme Activation: A Snapshot of the Gold Rush. Journal of Medicinal Chemistry, 2022, 65, 14289-14304.	2.9	2
205	Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance. Cancer Discovery, 2023, 13, 170-193.	7.7	6
206	Role of protein phosphorylation in cell signaling, disease, and the intervention therapy. MedComm, 2022, 3, .	3.1	21
207	Nitriles: an attractive approach to the development of covalent inhibitors. RSC Medicinal Chemistry, 2023, 14, 201-217.	1.7	11
208	AV-101, a Novel Inhaled Dry Powder Formulation of Imatinib, in Healthy Adult Participants: A Phase 1 Single and Multiple Ascending Dose Study. ERJ Open Research, 0, , 00433-2022.	1.1	5
209	Design, Synthesis, and In Vitro Mitotic Evaluation of 3â€Aminoâ€Isoquinolinones as Anticancer Agents. ChemistrySelect, 2022, 7, .	0.7	0
210	Proteomic characterization of post-translational modifications in drug discovery. Acta Pharmacologica Sinica, 2022, 43, 3112-3129.	2.8	11
211	Interaction of Masitinib with Organic Cation Transporters. International Journal of Molecular Sciences, 2022, 23, 14189.	1.8	4
212	Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors. Frontiers in Chemistry, 0, 10, .	1.8	2
213	Deciphering the Role and Signaling Pathways of PKCÎ± in Luminal A Breast Cancer Cells. International Journal of Molecular Sciences, 2022, 23, 14023.	1.8	1
214	Targeting Gatekeeper Mutations for Kinase Drug Discovery. Journal of Medicinal Chemistry, 2022, 65, 15540-15558.	2.9	14
215	Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update. Pharmacological Research, 2023, 187, 106552.	3.1	99
216	Clerodane diterpene induces apoptosis/anoikis and suppresses migration and invasion of human bladder cancer cells through the histone deacetylases, integrinâ€“focal adhesion kinase, and matrix metalloproteinase 9 signalling pathways. Human and Experimental Toxicology, 2022, 41, 096032712211430.	1.1	1
217	A frequent PLCÎ³1 mutation in adult T-cell leukemia/lymphoma determines functional properties of the malignant cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2023, 1869, 166601.	1.8	1

#	Article	IF	Citations
218	Dual activity inhibition of threonine aspartase 1 by a single bisphosphate ligand. RSC Advances, 2022, 12, 34176-34184.	1.7	1
219	Nanoluciferase-based complementation assays to monitor activation, modulation and signaling of receptor tyrosine kinases (RTKs). Methods in Enzymology, 2022, , .	0.4	0
220	Antitumor pharmacological research in the era of personalized medicine. Acta Pharmacologica Sinica, 2022, 43, 3015-3020.	2.8	4
221	N1-(3-(Trifluoromethyl)Phenyl) Isophthalamide Derivatives as Promising Inhibitors of Vascular Endothelial Growth Factor Receptor: Pharmacophore-Based Design, Docking, and MM-PBSA/MM-GBSA Binding Energy Estimation. , 0, , .		0
222	Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets. Pharmaceuticals, 2022, 15, 1478.	1.7	1
223	The coming decade in precision oncology: six riddles. Nature Reviews Cancer, 2023, 23, 43-54.	12.8	52
224	Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises. Cancers, 2022, 14, 6257.	1.7	5
225	The scientific career and life of Edmond H. Fischerâ€”A personal tribute. IUBMB Life, 2023, 75, 284-288.	1.5	0
226	Discovery of 10H-Benzo[b]pyrido[2,3-e][1,4]oxazine AXL Inhibitors via Structure-Based Drug Design Targeting c-Met Kinase. Journal of Medicinal Chemistry, 2023, 66, 220-234.	2.9	4
227	Practical Recommendations for the Manipulation of Kinase Inhibitor Formulations to Age-Appropriate Dosage Forms. Pharmaceutics, 2022, 14, 2834.	2.0	1
228	Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection. Clinical Proteomics, 2022, 19, .	1.1	3
229	Identification of PTPN22 as a potential genetic biomarker for abdominal aortic aneurysm. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
230	MSC-1186, a Highly Selective Pan-SRPK Inhibitor Based on an Exceptionally Decorated Benzimidazole-Pyrimidine Core. Journal of Medicinal Chemistry, 2023, 66, 837-854.	2.9	2
231	Advances in computational methods for ligand binding kinetics. Trends in Biochemical Sciences, 2023, 48, 437-449.	3.7	11
232	Drug Repositioning Applied to Cardiovascular Disease in Mucopolysaccharidosis. Life, 2022, 12, 2085.	1.1	1
234	Protein Kinase Inhibitors as a New Target for Immune System Modulation and Brain Cancer Management. International Journal of Molecular Sciences, 2022, 23, 15693.	1.8	0
236	Facile Synthesis of Zinc Indium Oxide Nanofibers Distributed with Low Content of Silver for Superior Antibacterial Activity. Small Structures, 2023, 4, .	6.9	26
237	Identification of LRRK2 Inhibitors through Computational Drug Repurposing. ACS Chemical Neuroscience, 2023, 14, 481-493.	1.7	6

#	Article	IF	Citations
238	Identification and validation of a novel ferroptosis-related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma. Frontiers in Immunology, 0, 13, .	2.2	3
239	Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spacesâ€"A Review. Pharmaceutics, 2023, 15, 239.	2.0	1
240	Dual ligand approach increases functional group tolerance in the Pd-catalysed Câ€"H arylation of N-heterocyclic pharmaceuticals. Chemical Science, 2023, 14, 1176-1183.	3.7	4
241	Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery. Pharmaceutics, 2023, 15, 59.	2.0	14
242	MS/MS-Based Molecular Networking: An Efficient Approach for Natural Products Dereplication. Molecules, 2023, 28, 157.	1.7	11
243	Cooperation of structural motifs controls drug selectivity in cyclin-dependent kinases: an advanced theoretical analysis. Briefings in Bioinformatics, 2023, 24, .	3.2	4
244	NaClOâ€Mediated Cross Installation of Indoles and Azoles Benefits Anticancer Hit Discovery. ChemMedChem, 2023, 18, .	1.6	1
245	Identification of Activated Cdc42-Associated Kinase Inhibitors as Potential Anticancer Agents Using Pharmacoinformatic Approaches. Biomolecules, 2023, 13, 217.	1.8	2
246	Inhibition of Abl Kinase by Imatinib Can Rescue the Compromised Barrier Function of 22q11.2DS Patient-iPSC-Derived Bloodâ€"Brain Barriers. Cells, 2023, 12, 422.	1.8	1
248	Resistance to a tyrosine kinase inhibitor mediated by changes to the conformation space of the kinase. Physical Chemistry Chemical Physics, 2023, 25, 6175-6183.	1.3	1
249	Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling. Molecules, 2023, 28, 943.	1.7	3
250	An affinity-directed phosphatase, AdPhosphatase, system for targeted protein dephosphorylation. Cell Chemical Biology, 2023, 30, 188-202.e6.	2.5	4
252	Drug discovery: Standing on the shoulders of giants. , 2023, , 207-338.		0
253	Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3Î² and DYRK1A Kinases: A Structural Perspective. Journal of Medicinal Chemistry, 2023, 66, 4009-4024.	2.9	13
254	A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19. , 2023, 20, 351-364.		5
255	Strategies for Competitive Activityâ€Based Protein Profiling in Small Molecule Inhibitor Discovery and Characterization. Israel Journal of Chemistry, 2023, 63, .	1.0	1
256	Design, synthesis and bioevaluation of 1,2,4-thiadiazolidine-3,5-dione derivatives as potential GSK-3Î² inhibitors for the treatment of Alzheimer's disease. Bioorganic Chemistry, 2023, 134, 106446.	2.0	4
257	Analysis of intracellular tyrosine phosphorylation in circulating neutrophils as a rapid assay for the in vivo effect of oral tyrosine kinase inhibitors. Frontiers in Pharmacology, 0, 14, .	1.6	0

#	Article	IF	Citations
258	Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research. Journal of Medicinal Chemistry, 2023, 66, 1700-1711.	2.9	11
259	Computational Approaches to Enzyme Inhibition by Marine Natural Products in the Search for New Drugs. Marine Drugs, 2023, 21, 100.	2.2	4
260	Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies. Frontiers in Oncology, 0, 13, .	1.3	4
262	2-Ethynylbenzaldehyde-Based, Lysine-Targeting Irreversible Covalent Inhibitors for Protein Kinases and Nonkinases. Journal of the American Chemical Society, 2023, 145, 3844-3849.	6.6	10
263	Gatekeeper mutations activate FGF receptor tyrosine kinases by destabilizing the autoinhibited state. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	5
264	Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases. Viruses, 2023, 15, 568.	1.5	2
265	Kinome inhibition states and multiomics data enable prediction of cell viability in diverse cancer types. PLoS Computational Biology, 2023, 19, e1010888.	1.5	1
266	Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities. Journal of Medicinal Chemistry, 2023, 66, 3135-3172.	2.9	6
267	Artificial Intelligence-Based Computational Screening and Functional Assays Identify Candidate Small Molecule Antagonists of PTPmu-Dependent Adhesion. International Journal of Molecular Sciences, 2023, 24, 4274.	1.8	2
268	Strategy toward Kinase-Selective Drug Discovery. Journal of Chemical Theory and Computation, 2023, 19, 1615-1628.	2.3	7
269	Protein kinases: Role of their dysregulation in carcinogenesis, identification and inhibition. Drug Research, 2023, 73, 189-199.	0.7	4
270	Cancer Therapy. , 2023, , 483-534.		0
271	Addressing Transcriptional Dysregulation in Cancer through CDK9 Inhibition. Biochemistry, 2023, 62, 1114-1123.	1.2	6
272	Management of the adverse effects of targeted therapy for cancer. Journal of the Korean Medical Association, 2023, 66, 105-111.	0.1	0
273	Coupling substrate-trapping with proximity-labeling to identify protein tyrosine phosphatase PTP1B signaling networks. Journal of Biological Chemistry, 2023, 299, 104582.	1.6	8
274	Thereâ€™s more to enzyme antagonism than inhibition. Bioorganic and Medicinal Chemistry, 2023, 82, 117231.	1.4	0
275	Applications and prospects of cryo-EM in drug discovery. Military Medical Research, 2023, 10, .	1.9	2
276	Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases. Journal of Medicinal Chemistry, 2023, 66, 4106-4130.	2.9	11

#	Article	IF	Citations
277	Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases. Frontiers in Pharmacology, 0, 14, .	1.6	7
278	Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022. International Journal of Molecular Sciences, 2023, 24, 5190.	1.8	2
280	Human Polo-like Kinase Inhibitors as Antiplasmodials. ACS Infectious Diseases, 2023, 9, 1004-1021.	1.8	2
281	LIMK2 promotes melanoma tumor growth and metastasis through G3BP1-ESM1 pathway-mediated apoptosis inhibition. Oncogene, 2023, 42, 1478-1491.	2.6	1
282	Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma. Nature Reviews Cancer, 2023, 23, 335-346.	12.8	4
284	Precision oncology comes of age. JAAPA: Official Journal of the American Academy of Physician Assistants, 2023, 36, 28-31.	0.1	1
285	Golgi-Targeting Anticancer Natural Products. Cancers, 2023, 15, 2086.	1.7	2
286	2â€Phenylquinazolinâ€4(3H)â€one scaffold as newly designed, synthesized VEGFRâ€2 allosteric inhibitors with potent cytotoxicity through apoptosis. Archiv Der Pharmazie, 2023, 356, .	2.1	2
287	First electrochemical investigation of new generation antineoplastic agent ceritinib at a boron-doped diamond electrode based on the pre-enrichment effect of anionic surfactant. Journal of the Iranian Chemical Society, 2023, 20, 1729-1742.	1.2	2
288	Structureâ€“Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017â€“Present). Pharmaceuticals, 2023, 16, 534.	1.7	7
289	Screening of natural product libraries in MCF7 cell line reveals the pro-apoptotic properties of Î² tetralone. Journal of Biomolecular Structure and Dynamics, 2024, 42, 876-884.	2.0	0
290	A korszerÅ± gyÃ³gyszerszint-monitorozÃ¡s szerepe az Ãºj tÃ¡pusÃº, kis molekulasÃºlyÃº, specifikus molekulÃ¡ris cÃ©lponttal rendelkezÅ‘, per os formÃ¡ban szedhetÅ‘ onkolÃ³giai gyÃ³gyszerek alkalmazÃ¡sa sorÃ¡n. Transfusio, 2022, 54, 174-183.	0.0	0
291	A New Wave of Targeting â€˜Undruggableâ€™ Wnt Signaling for Cancer Therapy: Challenges and Opportunities. Cells, 2023, 12, 1110.	1.8	8
292	Imatinib Analogs in Chronic Myeloid Leukemia: a Systematic Qualitative Review. Current Pharmacology Reports, 0, , .	1.5	0
293	Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy. Strahlentherapie Und Onkologie, 2023, 199, 1091-1109.	1.0	3
294	Setting sail: Maneuvering SHP2 activity and its effects in cancer. Advances in Cancer Research, 2023, , .	1.9	0
295	Rule of five violations among the FDA-approved small molecule protein kinase inhibitors. Pharmacological Research, 2023, 191, 106774.	3.1	11
296	A kinome-wide CRISPR screen identifies CK1Î± as a target to overcome enzalutamide resistance of prostate cancer. Cell Reports Medicine, 2023, 4, 101015.	3.3	2

#	Article	IF	Citations
297	MKK4 Inhibitorsâ€"Recent Development Status and Therapeutic Potential. International Journal of Molecular Sciences, 2023, 24, 7495.	1.8	2
304	Anticancer drugs acting on signaling pathways, part 1: Tyrosine kinase inhibitors. , 2023, , 493-563.		0
320	Exploring Allosteric Inhibitors of Protein Tyrosine Phosphatases Through High-Throughput Screening. Methods in Molecular Biology, 2023, , 235-245.	0.4	0
324	Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	68
333	Opportunities and challenges of protein-based targeted protein degradation. Chemical Science, 2023, 14, 8433-8447.	3.7	3
339	Editorial: Functional screening for cancer drug discovery: from experimental approaches to data integration. Frontiers in Genetics, 0, 14, .	1.1	1
350	HYDROGEN/DEUTERIUM EXCHANGE-MASS SPECTROMETRY IN MEDICINAL CHEMISTRY. Medicinal Chemistry Reviews, 0, , 465-487.	0.1	0
351	Principles of Clinical Oncology and Systemic Treatments. , 2023, , 225-246.		0
357	(Benz)imidazoles. , 2023, , 227-256.		0
368	CaMKK2 as an emerging treatment target for bipolar disorder. Molecular Psychiatry, 2023, 28, 4500-4511.	4.1	0
374	2-Aminopyrimidine. , 2023, , 391-404.		0
445	Recent Advances in RNA m6A Modification in Solid Tumors and Tumor Immunity. Cancer Treatment and Research, 2023, , 95-142.	0.2	0
460	Molecular Implications of BCR-ABL1 in Hematological Malignancies. , 2023, , .		0
471	Heart-on-a-chip systems: disease modeling and drug screening applications. Lab on A Chip, 2024, 24, 1494-1528.	3.1	0
485	Krebstherapie. , 2024, , 553-613.		0